Therapeutic efficacy of a combination of a β1-adrenoreceptor (AR) blocker and β2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a β1-AR blocker plus angiotensin-converting enzyme inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 1, 2009, Pages 178-185

  Ahmet, Ismail ^a   Morrell, Chris ^a   Lakatta, Edward G ^a   Talan, Mark I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; FENOTEROL; METOPROLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRESSLER SYNDROME; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HISTOPATHOLOGY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEART FAILURE; MALE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; VENTRICULAR REMODELING;

EID: 70349308404     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.157107     Document Type: Article

References (40)

1. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, and Talan MI (2004) Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 110:1083-1090. (Pubitemid 39319006)
2. Ahmet I, Krawczyk M, Zhu W, Woo AY, Morrell C, Poosala S, Xiao RP, Lakatta EG, and Talan MI (2008) Cardioprotective and survival benefits of long-term combined therapy with β2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. J Pharmacol Exp Ther 325:491-499. (Pubitemid 351574789)
3. Ahmet I, Lakatta EG, and Talan MI (2005) Pharmacological stimulation of beta2- adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy. Heart Fail Rev 10:289-296.
4. Anand IS and Florea VG (2008) Traditional and novel approaches to management of heart failure: successes and failures. Cardiol Clin 26:59-72, vi.
5. Anversa P, Cheng W, Liu Y, Leri A, Redaelli G, and Kajstura J (1998) Apoptosis and myocardial infarction. Basic Res Cardiol 93 (Suppl 3):8-12.
6. Brodde OE, Michel MC, and Zerkowski HR (1995) Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Cardiovasc Res 30:570-584.
7. Brower GL, Levick SP, and Janicki JS (2007) Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol 292:H3057-H3064.
8. Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG, and Crow MT (2000) The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G. (i)-dependent coupling to phosphatidylinositol 3-kinase. Circ Res 87:1172-1179.
9. Communal C, Singh K, Sawyer DB, and Colucci WS (1999) Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100:2210-2222.
10. CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-1435.
11. Fedorov VN, Sal'nikov EV, Sidorov AV, Bogatushin AV, and Fateev MM (2006) Survival of rats with experimental chronic heart failure depending on pharmacodynamic and pharmacokinetic parameters of angiotensin-converting enzyme inhibitor and beta-adrenoreceptor blockers. Bull Exp Biol Med 141:40-43.
12. Goldman S and Raya TE (1995) Rat infarct model of myocardial infarction and heart failure. J Card Fail 1:169-177.
13. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, and Eichhorn EJ (1995) Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25:1154-1161.
14. Heart Failure Society Of America (2006) HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12:e1-e2.
15. Hochman JS and Bulkley BH (1982) Expansion of acute myocardial infarction: an experimental study. Circulation 65:1446-1450.
16. Hon JK and Yacoub MH (2003) Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann Thorac Surg 75 (6 Suppl):S36-S41.
17. Hügel S, Horn M, de Groot M, Remkes H, Dienesch C, Hu K, Ertl G, and Neubauer S (1999) Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction. Am J Physiol 277:H2167-H2175. (Pubitemid 30048135)
18. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, and Pauly NC (1995) A clinical trial of the angiotensinconverting- enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333:1670-1676.
19. Krzemiński TF, Nozyński JK, Grzyb J, and Porc M (2008) Widespread myocardial remodeling after acute infarction in rat. Feature for heart failure progression. Vasc Pharmacol 48:100-108.
20. Ma M, Watanabe K, Wahed MI, Inoue M, Sekiguchi T, Kouda T, Ohta Y, Nakazawa M, Yoshida Y, Yamamoto T, et al. (2001) Inhibition of progression of heart failure and expression of TGF-beta 1 mRNA in rats with heart failure by the ACE inhibitor quinapril. J Cardiovasc Pharmacol 38 (Suppl 1):S51-S54. (Pubitemid 33104683)
21. Mann DL, Kent RL, Parsons B, and Cooper G 4th (1992) Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85:790-804.
22. Martin RM, Dunn NR, Freemantle SN, and Mann RD (1998) Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. Thorax 53:558-562.
23. Mazza A, Tikhonoff V, Casiglia E, and Pessina AC (2005) Predictors of congestive heart failure mortality in elderly people from the general population. Int Heart J 46:419-431.
24. Pfeffer JM, Pfeffer MA, and Braunwald E (1987) Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation 75:I149-I155.
25. Pfeffer MA and Braunwald E (1990) Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81:1161-1172.
26. Pfeffer MA, Braunwald E, MoyéLA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, and Flaker GC (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669-677.
27. Pfeffer MA, Pfeffer JM, Steinberg C, and Finn P (1985) Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 72:406-412. (Pubitemid 15019891)
28. Pearce N, Crane J, Burgess C, Beasley R, and Jackson R (1989) Fenoterol and asthma mortality. Lancet 1:1196-1197.
29. Port JD and Bristow MR (2001) Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 33:887-905. (Pubitemid 32545325)
30. Selye H, Bajusz E, Grasso S, and Mendell P (1960) Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 11:398-407.
31. Shizukuda Y and Buttrick PM (2002) Subtype specific roles of β-adrenergic receptors in apoptosis of adult rat ventricular myocytes. J Mol Cell Cardiol 34:823-831. (Pubitemid 35205184)
32. The AIRE Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828.
33. The CIBIS II Investigators (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9-13.
34. The MERIT-HF Investigators (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007.
35. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302.
36. Watanabe K, Ma M, Wen J, Tachikawa H, Kodama M, Aizawa Y, Yamaguchi K, and Takahashi T (2004) Comparative effects of quinapril with enalapril in rats with heart failure. Pharmacology 71:157-161. (Pubitemid 38716231)
37. Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, and Böhm M (2008) RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 97:418-431.
38. Wollert KC and Drexler H (1999) The renin-angiotensin system and experimental heart failure. Cardiovasc Res 43:838-849. (Pubitemid 29413183)
39. Xiao RP, Zhu W, Zheng M, Chakir K, Bond R, Lakatta EG, and Cheng H (2004) Subtype-specific β-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci 25:358-365. (Pubitemid 38829489)
40. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A 98:1607-1612.